Cat. No.: X24-08-YM289
Integrin inhibitor, Cyclo-RGDfK, Purity ≥98%
Synonym: 161552-03-0; Cyclic RGDFK peptide; 2-[(2S,5R,8S,11S)-8-(4-Aminobutyl)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
- CAS Number: 161552-03-0
- Compound CID: 10196873
Product Size
1 mg; 5 mg; 10 mg; 50 mg
Properties
Description
Cyclo-RGDfK is an effective cytoskeleton inhibitor, that has the ability to prevent the pathway of cytoskeletal signaling by inhibiting integrin. It targets the αvβ3.
Molecular Formula
C27H41N9O7
Targets
αvβ3: 0.94 nM (IC50)
Titer
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects
Stability
In its lyophilized form, the chemical remains stable for 36 months.
Quality Level
Research grade
Applications
Cyclo-RGDfK is a cytoskeletal signaling inhibitor that can be studied extensively for its potential therapeutic applications in the treatment of cancer and other diseases involving aberrant cell adhesion and migration.
Storage
Store at -20ºC, and keep desiccated.
Related Products
- Integrin inhibitor, Zaurategrast, Purity ≥98%
- Integrin inhibitor, Cilengitide trifluoroacetate, Purity ≥98%
- Integrin inhibitor, Cilengitide, Purity ≥98%
- Integrin inhibitor, Firategrast, Purity ≥98%
- Integrin inhibitor, Pyrintegrin, Purity ≥98%
- Integrin inhibitor, A-205804, Purity ≥98%
